Medicines for Pediatric Patients-Biopharmaceutical, Developmental, and Regulatory Considerations

Area of Science:

• Pediatric Medicine
• Translational Science
• Regulatory Science

Background:

• Recent legislation in Europe and the US has increased pediatric clinical trials.
• Significant challenges persist in pediatric drug development due to physiological differences and patient heterogeneity.
• Off-label drug use in children leads to adverse events and reduced efficacy.

Purpose of the Study:

• To discuss current developments and outstanding issues in pediatric medicine and drug development.
• To highlight the scientific debate surrounding the Pediatric Biopharmaceutical Classification System and in vitro models.
• To emphasize the need for improved physiologically based pharmacokinetic modeling in pediatric populations.

Main Methods:

• Commentary based on current scientific literature and regulatory landscapes.
• Discussion of challenges in pediatric drug formulation and bioequivalence.
• Exploration of advanced modeling techniques like physiologically based pharmacokinetic modeling.

Main Results:

• Increased initiation of clinical trials in the pediatric population.
• Ongoing debate on the applicability of in vitro dissolution for bioequivalence waivers.
• Identification of knowledge gaps in pediatric drug development and dose definition.
• Potential of physiologically based pharmacokinetic modeling to address some challenges.

Conclusions:

• Pediatric drug development requires addressing unique physiological and heterogeneity challenges.
• Further research and development of in vitro models and pharmacokinetic modeling are essential.
• Global recognition and funding initiatives like the Innovative Medicines Initiative are crucial for progress.